Whether our classification tool can be used to distinguish high-risk postmenopausal patients with primary ER+/HER2– breast cancer that do not benefit from adjuvant tamoxifen should be validated in a retrospective independent trial cohort before it can be implemented in the clinic. This evidence concerns the gene ERBB2 and breast carcinoma.